The True Story
Behind Puncture

In the late 1980s, a Texas engineer named Thomas Shaw invented a syringe with a retractable needle. The concept was elegantly simple: after injection, the needle automatically retracts into the barrel, making it physically impossible to cause a needlestick injury. He called it the VanishPoint.

Shaw’s early development work received $649,497 across three NIH SBIR awards from 1992 through 1994, made to his company Checkmate Engineering. The awards supported work on a single-use retractable syringe before Retractable Technologies was incorporated.

Shaw founded Retractable Technologies, Inc. (RTI) in Little Elm, Texas, and prepared to bring his VanishPoint syringe to market. But when he approached hospitals, he hit a wall — not a technical wall, but a financial one. The Group Purchasing Organizations (GPOs) that controlled hospital supply chains refused to carry it.

In 1986, Congress granted Group Purchasing Organizations a "safe harbor" exemption from Medicare anti-kickback laws. The intent was to let GPOs negotiate bulk discounts for hospitals. The result was the opposite: GPOs began collecting fees from the very suppliers they were supposed to negotiate against, creating a perverse incentive to maintain exclusive contracts with dominant manufacturers rather than find the safest or most cost-effective products.

By the late 1990s, five GPOs controlled over 90% of hospital purchasing in the United States — more than $130 billion in annual medical supply spending. Becton Dickinson (BD), the world's largest syringe manufacturer, held approximately 90% of the U.S. conventional syringe market and paid GPOs hundreds of millions in administrative fees to maintain exclusive dealing arrangements.

When Thomas Shaw's retractable syringe threatened to disrupt BD's market share, the GPOs had every financial reason to block it. And they did — for over a decade, while healthcare workers continued to be injured and infected at catastrophic rates.

Mike Weiss was brilliant, charismatic, and self-destructive. A graduate of the University of Houston Law Center, he was the kind of trial lawyer who could command a courtroom with raw intellect and fearless advocacy. He was also a severe drug addict — a contradiction that defined both his genius and his tragedy.

In 1998, when Thomas Shaw's case landed on his desk, Weiss recognized immediately what it represented: not just a product liability dispute, but a systemic conspiracy to prioritize corporate profits over human lives. He threw himself into the case with obsessive intensity, spending nights in the office building the antitrust theory that would eventually bring down the monopoly.

Paul Danziger was the methodical, disciplined partner — a Northwestern Law graduate who had practiced international business law in Bangkok and Ho Chi Minh City before returning to Houston. Where Weiss was instinct and fire, Danziger was strategy and endurance. Together, they formed a two-man law firm taking on a $130 billion industry.

They filed a federal antitrust lawsuit in the Eastern District of Texas on behalf of Retractable Technologies against the GPOs and Becton Dickinson. The complaint alleged violations of the Sherman Antitrust Act and Clayton Act — exclusive dealing arrangements, tying agreements, and group boycotts designed to prevent safety devices from reaching the market.

Mike Weiss never saw the case resolved. He never saw the settlements, the legislation, or the film that would tell his story. His death left Paul Danziger alone — a single attorney against an army of corporate defense lawyers representing the largest medical supply companies in the world.

But Danziger refused to let the fight die with his partner. He continued the litigation alone, spending years in discovery, surviving motions to dismiss, and building the evidentiary record that would eventually force the industry to settle. It was a decision that required not just legal skill, but extraordinary personal resolve.

The Needlestick Safety and Prevention Act became law on November 6, 2000, before the 2004 Becton Dickinson settlement. The public legislative record describes a broader response to occupational sharps injuries, safer-device developments, OSHA materials, and congressional consideration. The law required employers to consider appropriate commercially available safer medical devices and gave healthcare workers a voice in selecting safety equipment.

Then came the settlements. In 2003, Retractable Technologies reached agreements with GPOs Novation, Premier, and Tyco. On July 2, 2004, Retractable Technologies announced a $100 million settlement with Becton Dickinson.

Retractable Technologies said the settlement positioned the company to market its products to customers in the United States and overseas. The company announcement is a contemporaneous source record; it is not an independent finding about the settlement’s market-wide effects.

After the case concluded, Paul Danziger wrote an autobiographical screenplay about his partnership with Mike Weiss and their fight against the medical supply monopoly. He personally financed the production and partnered with directors Adam and Mark Kassen — with Mark also starring as Danziger himself.

Chris Evans was cast as Mike Weiss — a role that required portraying both the attorney's brilliance and his devastating addiction. The film was shot on location in Houston, Texas, and premiered at the 2011 Tribeca Film Festival. In January 2012, it won the inaugural Texas Independent Film Award from the Houston Film Critics Society.

The supporting cast includes Vinessa Shaw as Vicky, Brett Cullen as Nathaniel Price, Marshall Bell as Thomas Shaw (the inventor), and Michael Biehn as Red. The film captures not just the legal thriller aspects of the case, but the human cost — the friendship between two men, the weight of addiction, and the question of what justice means when one person doesn't live to see it.

The Retractable Technologies v. Becton Dickinson case didn't just produce a settlement — it changed an industry. The Needlestick Safety and Prevention Act remains federal law. Safety-engineered sharps devices are now standard in American hospitals. The WHO has since issued global mandates for injection safety, and needlestick injury rates have declined significantly in countries that adopted safety needle requirements.

Paul Danziger went on to co-found Danziger & De Llano, LLP with Rod De Llano in 1999. The firm became a nationally recognized mesothelioma and asbestos litigation practice, applying the same tenacity that drove the needle safety case to fight for families affected by corporate negligence in the asbestos industry. The firm has recovered over $2 billion for clients across the United States.

The pattern is the same one Weiss and Danziger identified in 1998: corporations prioritizing profits over human safety, using market power to suppress alternatives, and relying on regulatory capture to avoid accountability. The needle case proved that two people with the right evidence and enough determination can break that pattern.